Su Xuan, He Hui-Chan, Ye Zu-Lu, Zhou Da-Lei, Liu Qing, Yang Xin-Hua, Long Ya-Kang, Tang Tao, Ma Jiang-Jun, Xu Bo-Heng, Chen Wei-Chao, He Cai-Yun, Yang An-Kui
Department of Head and Neck, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Blood Transfusion, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Front Oncol. 2020 Oct 15;10:535893. doi: 10.3389/fonc.2020.535893. eCollection 2020.
Few reports from China provide confirmed evidence of the effectiveness of the larynx preservation strategy compared with surgery on the treatment of laryngeal and hypopharyngeal cancers. This study assessed the clinical outcomes of patients with locally advanced laryngeal and hypopharyngeal cancers treated with larynx preservation and determined the optimal larynx preservation procedure.
Data of 1,494 patients treated with total laryngectomy or larynx preservation between 2006 and 2014 were retrieved from the database of Sun-Yat Sen University Cancer Center in Guangzhou, China, and 366 eligible patients were selected for final analysis. The clinical outcomes of 228 patients received total laryngectomy and 138 patients received larynx preservation treatments, which comprises induction followed by radiotherapy and concurrent radio-chemotherapy, were compared.
There was no statistical difference in the 3-, 5-, and 10-year PFS and OS in patients received larynx preservation compared with patients treated with laryngectomy. With respect to T stage, a better overall OS in T2-stage disease (P = 0.036) but poorer PFS (P = 0.005) in T3-stage disease was observed in the larynx preservation group compared with the surgery group in Univariate analysis. T3-stage disease had poorer PFS in multivariable analysis (P = 0.022). With larynx preservation intent, induction chemotherapy followed by radiotherapy showed no advantage in the control of disease progression and survival compared with concurrent chemoradiotherapy. The patient subpopulations who received efficacy assessment after induction chemotherapy exhibited significantly longer PFS and OS compared with those without efficacy assessment.
This is the largest sample size study on larynx preservation treatment for laryngeal and hypopharyngeal cancers in China. Our results indicated that larynx preservation treatments did not jeopardize the survival of patients with advanced resectable laryngeal or hypopharyngeal cancers. Efficacy assessment should be emphasized in induction chemotherapy.
与手术治疗喉癌和下咽癌相比,中国很少有报告提供喉保留策略有效性的确凿证据。本研究评估了接受喉保留治疗的局部晚期喉癌和下咽癌患者的临床结局,并确定了最佳的喉保留手术方式。
从中国广州中山大学肿瘤防治中心数据库中检索2006年至2014年间接受全喉切除术或喉保留治疗的1494例患者的数据,最终选取366例符合条件的患者进行分析。比较了228例行全喉切除术患者和138例接受喉保留治疗患者的临床结局,后者包括诱导化疗后放疗及同步放化疗。
与接受喉切除术的患者相比,接受喉保留治疗的患者在3年、5年和10年的无进展生存期(PFS)和总生存期(OS)方面无统计学差异。单因素分析显示,与手术组相比,喉保留组T2期疾病的总体OS较好(P = 0.036),但T3期疾病的PFS较差(P = 0.005)。多因素分析显示T3期疾病的PFS较差(P = 0.022)。出于保留喉的目的,诱导化疗后放疗与同步放化疗相比,在控制疾病进展和生存方面无优势。诱导化疗后接受疗效评估的患者亚组与未接受疗效评估的患者相比,PFS和OS显著更长。
这是中国关于喉癌和下咽癌喉保留治疗的样本量最大的研究。我们的结果表明,喉保留治疗不会危及晚期可切除喉癌或下咽癌患者的生存。诱导化疗中应强调疗效评估。